Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor
- Conditions
- HIV Infections
- Registration Number
- NCT00038519
- Lead Sponsor
- Abbott
- Brief Summary
The purpose of this study is to study the safety and efficacy of Amprenavir/ritonavir or saquinavir/ritonavir in HIV infected patients that have failed Kaletra as their second protease inhibitor based HAART.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 16
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Proportion of subjects with plasma HIV RNA levels below the limit of quantification (400 copies/mL) at week 24 and the time until loss of virologic response through week 48
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (52)
Phoenix Body Positive, Inc.
🇺🇸Phoenix,, Arizona, United States
AIDS Health Care Foundation - Research Center
🇺🇸Los Angeles, California, United States
20th Avenue Medical Center Kaiser Permanente
🇺🇸Denver, Colorado, United States
University of Colorado Health Sciences Center
🇺🇸Denver, Colorado, United States
IDC Research Initiative
🇺🇸Altamonte Springs, Florida, United States
Associates in Research
🇺🇸Fort Myers, Florida, United States
Gary J. Richmond, M.D.
🇺🇸Ft. Lauderdale, Florida, United States
University of Miami School of Medicine
🇺🇸Miami, Florida, United States
Infectious Disease Research Institute, Inc.
🇺🇸Tampa, Florida, United States
AIDS Research Consortium of Atlanta, Inc.
🇺🇸Atlanta, Georgia, United States
Scroll for more (42 remaining)Phoenix Body Positive, Inc.🇺🇸Phoenix,, Arizona, United States